Forte Biosciences, Inc. (FBRX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Dallas, TX, United States. The current CEO is Paul A. Wagner.
FBRX has IPO date of 2017-04-13, 14 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $450.17M.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
